| 证券代码 | NVLN.O |
| 证券名称 | Novelion Therapeutics Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 1988-10-28 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Novelion Therapeutics Inc. |
| 注册地址 | 加拿大不列颠哥伦比亚省 |
| 办公地址 | 887 Great Northern Way, Suite 250, Vancouver, B.C., Canada |
| 成立日期 | 1981 |
| 董事会主席 | - |
| 公司属地 | Canada 加拿大 |
| 公司网址 | www.novelion.com |
| 电话 | +1 (604) 707-7000 |
| 传真 | +1 (604) 707-7001 |
| 公司简介 | Novelion Therapeutics Inc. is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc. (Aegerion), which includes MYALEPT and JUXTAPID, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. |